LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
28 funds hold it · Insiders net selling
Net selling: insiders sold $6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 27, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.46 expected
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 27, 2026 | $0.53est. $0.46 | +14.49%beat | $209.3MSEC filing | +10.9%from $188.8M |
| Jun 30, 2026Reported Jul 28, 2026 | $0.54est. $0.45 | +20.38%beat | $204.1MSEC filing | +11.9%from $182.4M |
| Mar 31, 2026Reported May 5, 2026 | $0.48est. $0.39 | +22.87%beat | $194.3MSEC filing | +14.8%from $169.2M |
| Dec 31, 2025Reported Feb 24, 2026 | $0.49est. $0.44 | +10.38%beat | $197.9MAlpha Vantage | +18.1%from $167.5M |
| Sep 30, 2025Reported Oct 28, 2025 | $0.46est. $0.41 | +12.20%beat | $188.8MSEC filing | +21.9%from $154.9M |
| Jun 30, 2025Reported Jul 29, 2025 | $0.37est. $0.39 | -5.13%miss | $182.4MSEC filing | +14.8%from $158.8M |
| Mar 31, 2025Reported Apr 29, 2025 | $0.39est. $0.35 | +11.43%beat | $169.2MSEC filing | +10.4%from $153.2M |
| Dec 31, 2024Reported Feb 20, 2025 | $0.44est. $0.42 | +4.99%beat | $167.5MAlpha Vantage | +7.6%from $155.7M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $197.9M | $194.3M | $204.1M | $209.3M |
| Cost of what it sold | $104.5M | $95.8M | $95.8M | $98.3M |
| Gross profit | $93.4M | $98.5M | $108.4M | $111.0M |
| What it spent | ||||
| Research and development | $12.2M | $14.5M | $14.4M | $14.4M |
| Sales and admin | $86.0M | $76.5M | $76.6M | $83.6M |
| Other operating costs | -$23.3M | -$10.5M | $5.4M | $42.5M |
| Total operating expenses | $74.9M | $80.5M | $96.4M | $140.5M |
| What was left | ||||
| Operating profit | $18.6M | $18.0M | $11.9M | -$29.5M |
| Interest on debt | $5.9M | $6.0M | $17.2M | $5.7M |
| Profit before tax | $19.1M | $1.8M | $14.2M | -$26.8M |
| Tax | $5.8M | -$6.6M | $9.1M | $11.6M |
| Net profit | $13.3M | $8.3M | $5.0M | -$38.4M |
| EBITDA | $49.6M | $32.3M | $45.9M | -$2.0M |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
How Investors Are Reacting To Repligen (RGEN) Impairment Charges And Quarterly Loss
BearishNov 5In London, Repligen's CEO will join an analyst-led discussion on Nov. 18.
NeutralNov 5Repligen Corporation to Present at Jefferies Global Healthcare Conference
Leans bullishNov 4Repligen (RGEN) Stock Looks Reasonable Despite Its 35% Five Year Fall
NeutralNov 4Repligen (RGEN) Stock Price, Chart & Analysis
NeutralNov 3Repligen 'Very Confident' in Filtration Business Returning to Historical Growth Rates Next Year, RBC Says
BullishNov 3Weekly Recap: Higher 2026 guidance and phased manufacturing restructuring
BullishNov 2Stifel reiterates Buy on Repligen stock, keeps $207 target By Investing.com
BullishNov 220 macro signals shaping RGEN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
